Related Experiment Video
Updated: Jul 28, 2025

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
Imtiaz A Samjoo1, Christopher Drudge1, Sarah Walsh1
1Value & Evidence, EVERSANA™, Burlington, Ontario, Canada.
None:
Aim: To assess the relative efficacy of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (RMS) including newer therapies (ozanimod, ponesimod, ublituximab) using network meta-analysis (NMA). Materials & methods: Bayesian NMAs for annualised relapse rate (ARR) and time to 3-month and 6-month confirmed disability progression (3mCDP and 6mCDP) were conducted. Results: For each outcome, the three most efficacious treatments versus placebo were monoclonal antibody (mAb) therapies: alemtuzumab, ofatumumab, and ublituximab for ARR; alemtuzumab, ocrelizumab, and ofatumumab for 3mCDP; and alemtuzumab, natalizumab, and either ocrelizumab or ofatumumab (depending on the CDP definition used for included ofatumumab trials) for 6mCDP. Conclusion: The most efficacious DMTs for RMS were mAb therapies. Of the newer therapies, only ublituximab ranked among the three most efficacious treatments (for ARR).
Related Concept Videos
Dose-Response Relationship: Potency and Efficacy
Electroconvulsive Therapy
Drug Therapy
Antianxiety Medications
Comparing the Survival Analysis of Two or More Groups

